Heparine Leo

Heparine Leo is a pharmaceutical product that contains the active ingredient heparin sodium. It is supplied for intravenous administration and is marketed in the European Union as a prescription‑only anticoagulant. The formulation is designed to provide rapid anticoagulation by enhancing antithrombin III activity, thereby helping to prevent abnormal blood clot formation in various clinical settings.

Heparine Leo is indicated for several antithrombotic purposes where rapid anticoagulation is required.

- Prevention and treatment of venous thromboembolism (deep‑vein thrombosis and pulmonary embolism). - Prophylaxis of clot formation during cardiac surgery, coronary artery bypass grafting, and hemodialysis. - Management of acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction. - Thromboprophylaxis in patients undergoing major orthopedic procedures such as hip or knee replacement. - Anticoagulation for patients receiving extracorporeal membrane oxygenation (ECMO) or other extracorporeal circuits.

Heparine Leo may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common: - Minor bleeding at injection sites or from mucous membranes. - Small bruising or hematoma formation. - Transient elevation of liver enzymes. - Nausea or mild gastrointestinal discomfort. - Local irritation or phlebitis at the infusion site.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spontaneous spinal or epidural hematoma when used near the spine. - Severe liver injury or hepatic necrosis (rare).

When prescribing or administering Heparine Leo, clinicians should consider several safety factors.

- Assess baseline coagulation parameters (aPTT, platelet count) before initiation and monitor regularly. - Use caution in patients with a history of bleeding disorders, recent surgery, or trauma. - Evaluate renal and hepatic function, as impairment may affect drug clearance. - Avoid use in patients with known hypersensitivity to heparin or pork‑derived products. - Consider alternative anticoagulation in pregnant women, as safety data are limited. - Educate patients about signs of bleeding and when to seek medical attention.

Heparine Leo can interact with other agents that affect hemostasis or platelet function.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring. - High‑dose antiplatelet drugs such as clopidogrel or aspirin when bleeding risk is elevated. - Thrombolytic agents (e.g., alteplase, streptokinase) due to additive hemorrhagic risk.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase gastrointestinal bleeding. - Certain antibiotics (e.g., vancomycin) that can potentiate platelet dysfunction. - Herbal supplements such as ginkgo biloba, garlic, or ginseng that have antiplatelet properties. - Vitamin K antagonists, requiring close monitoring of INR and aPTT.